 RAMSEY, N.J. and BOCA RATON, Fla. and MARYVILLE, Tenn., Aug. 16, 2021 GLOBE NEWSWIRE -- ADMA Biologics, Inc. NASDAQ: ADMA ADMA, an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it has received U.S. Food and Drug Administration FDA approval for its ADMA BioCenters plasma collection facility located in Maryville, Tennessee. This plasma collection facility commenced operations and initiated source plasma collection in the fourth quarter of 2020. With todays approval, this facility is now FDA-licensed to collect and introduce into interstate commerce human source plasma for further manufacturing in the U.S. 